Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2007-03-27
2007-03-27
Monshipouri, Maryam (Department: 1656)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S015000, C435S194000, C536S023200
Reexamination Certificate
active
10637356
ABSTRACT:
Oncokinase fusion polypeptides associated with hyperproliferative disorders and the polynucleotides encoding for such fusion polypeptides are provided. The fusion polypeptides have a C-terminal tyrosine kinase domain fused to an N-terminal domain that is not normally fused to the C-terminal tyrosine kinase domain and they possess constitutively activated tyrosine kinase activity. Also provided are methods for detecting and identifying the fusion polypeptides and polynucleotides and methods of diagnosing disease conditions associated with the fusion polypeptides and polynucleotides. In addition, screening assays for identifying agents useful for treating disease conditions associated with such fusion polypeptides and polynucleotides are provided. Furthermore, methods of treating disease conditions associated with the presence of the fusion polypeptides are provided.
REFERENCES:
patent: 5521184 (1996-05-01), Zimmermann
patent: 5700822 (1997-12-01), Hirth et al.
patent: 6258812 (2001-07-01), Bold et al.
patent: 6573293 (2003-06-01), Tang et al.
patent: 2003/0171378 (2003-09-01), Griffin et al.
patent: WO 02/16351 (2002-02-01), None
Baxter et al., “The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA”, Human Molecular Genetics, vol. 11, No. 12, pp. 1391-1397 (2002).
Cools et al., “A Tyrosine Kinase Created by Fusion of the PDGFRA and FIP1L1 Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome”, The New England Journal of Medicine, vol. 348, No. 13, pp. 1201-1214 (2003).
Cross et al., “Tyrosine kinase fusion genes in chronic myeloproliferative diseases”, Leukemia, vol. 16, pp. 1207-1212 (2002).
Griffin et al., “Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome”, PNAS, vol. 100, No. 13, pp. 7830-7835 (2003).
Pardanani et al., “CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic masatocytosis associated with eosinophilia and predicts response to Imatinib therapy”, BLOOD First Edition Paper, published online Jul. 3, 2003; DOI 10.1182/blood-2003-05-1627.
Schaller et al., “Rapid and Complete Control of Idiopathic Hypereosinophilia with Imatinib Mesylate”, Medscape General Medicine 3(3), 5 pages (2001).
Briesewitz Roger
Griffin John H.
Hagenah Jeffrey A.
Monshipouri Maryam
Saxon Roberta P.
Theravance Inc.
LandOfFree
Oncokinase fusion polypeptides associated with... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oncokinase fusion polypeptides associated with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oncokinase fusion polypeptides associated with... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3723470